Rucaparib particles and uses thereof

Rucaparib particles with high SSA and controlled size address poor solubility issues, enhancing dissolution rates and treatment efficacy.

JP2024543323AInactive Publication Date: 2024-11-21CRITITECH INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024524999
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-10
Filing Date
2022-11-08
Publication Date
2024-11-21
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Poor water solubility and dissolution rates limit the in vivo bioavailability of many drugs, necessitating compositions that enhance dissolution rates.

Method used

Development of rucaparib particles with a high specific surface area (SSA) and controlled particle size, free of certain excipients, to improve dissolution properties.

Benefits of technology

The increased specific surface area and controlled particle size lead to enhanced dissolution rates, facilitating better drug absorption and reduced systemic concentrations, thereby improving treatment efficacy and reducing side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543323000006
    Figure 2024543323000006
  • Figure 2024543323000007
    Figure 2024543323000007
  • Figure 2024543323000008
    Figure 2024543323000008
Patent Text Reader

Abstract

At least 95% by weight of rucaparib and a specific surface area (SSA) of at least 12 m 2 / g particle compositions, methods for their use, and methods for their production are provided.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] cross reference This application claims priority to U.S. Provisional Patent Application No. 63 / 277,785, filed November 10, 2021, which is incorporated by reference in its entirety herein. [Background technology]

[0002] Dissolution rate is the main parameter in determining the rate and extent of drug absorption and bioavailability.Poor water solubility and poor in vivo dissolution are limiting factors for the in vivo bioavailability of many drugs.Therefore, in vitro dissolution rate is recognized as an important factor in drug development, and there is a need for methods and compositions for enhancing the dissolution rate of poorly soluble drugs. Summary of the Invention

[0003] In one aspect, the disclosure provides a composition comprising particles comprising at least 95% by weight of rucaparib, or a pharma- ceutically acceptable salt thereof, wherein the particles have a diameter of at least 12 mm. 2 In one embodiment, the particles have a specific surface area (SSA) of 12 m 2 / g~about 50m 2 / g. In another embodiment, the particles have a mean particle size by volume distribution (Dv50) of about 1.0 microns to about 10.0 microns in diameter. In one embodiment, the particles comprise an amorphous powder or are crystalline. In another embodiment, the rucaparib particles have an SSA of about 0.020 g / cm. 3 ~Approx. 0.300g / cm 3 In a further embodiment, the rucaparib particles have an average bulk density (not tapped density) of about 0.020 g / cm 3 ~Approx. 0.400g / cm 3 The average tap density is

[0004] In one embodiment, the particles are uncoated and are free of polymers, proteins, polyethoxylated castor oil, and polyethylene glycol glycerides, which are composed of mono-, di-, and triglycerides and mono- and diesters of polyethylene glycol. In another embodiment, the composition comprises a suspension further comprising a pharma- ceutically acceptable liquid carrier. In one embodiment, the suspension is aerosolized, and the mass median aerodynamic diameter (MMAD) of the aerosolized droplets of the suspension can be any suitable diameter for use, such as about 0.5 μm to about 6 μm in diameter. In a further embodiment, the composition is a dry powder composition, and the dry powder composition is aerosolized, and the MMAD of the aerosolized dry powder composition can be any suitable diameter for use, such as about 0.5 μm to about 6 μm in diameter. In one embodiment, the pharma- ceutically acceptable salt of rucaparib comprises rucaparib camsylate.

[0005] In another aspect, the present disclosure provides a method for treating a tumor, comprising administering to a subject having a tumor an amount of a composition of any embodiment or combination of embodiments of the present disclosure effective to treat the tumor. (a) (i) introducing into a nozzle inlet a solution comprising at least one solvent, including but not limited to ethanol, methanol, hexafluoroisopropanol (HFIP), dimethylformamide (DMF), dimethylsulfoxide (DMSO), or a combination thereof, and at least one solute, including rucaparib or a pharma- ceutically acceptable salt thereof, and (ii) introducing a compressed fluid into an inlet of a container defining a pressurizable chamber; (b) passing the solution through a nozzle orifice into a pressurizable chamber to generate an outlet stream of atomized droplets, the nozzle orifice being located 2 mm to 20 mm from a sonic energy source located within the outlet stream, the sonic energy source generating sonic energy having an amplitude of 10% to 100% during the passage, and the nozzle orifice having a diameter of 20 μm to 125 μm; (c) contacting the atomized droplets with a compressed fluid to cause removal of solvent from the atomized droplets to produce rucaparib particles comprising at least 95% rucaparib or a pharma- ceutically acceptable salt thereof, wherein the rucaparib particles are at least 2.5 mm in diameter; 2 / g specific surface area (SSA), optionally having an average particle size by volume distribution (Dv50) of about 1.0 microns to about 10.0 microns in diameter; The method is provided wherein steps (a), (b) and (c) are carried out under the supercritical temperature and pressure of the compressed fluid. [Brief description of the drawings]

[0006] [Figure 1] (A) Scanning electron microscopy photomicrographs of raw rucaparib at 1000x and (B) raw rucaparib at 5000x. [Diagram 2] Scanning electron microscopy micrographs of (A) rucaparib SC1 2000x, (B) rucaparib SC1 10,000x. [Diagram 3] Scanning electron microscopy micrographs of (A) rucaparib SC3 2000x and (B) rucaparib SC3 10,000x. [Figure 4] Scanning electron microscopy micrographs of (A) rucaparib SC4 2000x and (B) rucaparib SC4 10,000x. [Diagram 5] Scanning electron microscopy micrographs of (A) rucaparib SC5 2000x and (B) rucaparib SC5 10,000x. [Figure 6] Scanning electron microscopy micrographs of (A) rucaparib SC6 2000x and (B) rucaparib SC6 10,000x. [Figure 7] Scanning electron microscopy micrographs of (A) rucaparib SC7 2000x and (B) rucaparib SC7 10,000x. [Figure 8] Powder X-ray diffraction patterns for rucaparib experiments SC1, SC3, SC4, SC5, SC6, and SC7 compared to raw rucaparib [Figure 9] Graph showing dissolution of untreated rucaparib (raw) or treated rucaparib particles in 900 mL of 25% MeOH-water at 50 rpm. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0007] All cited references are incorporated herein by reference in their entirety. As used herein, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. All embodiments of any aspect of the present disclosure can be used in combination unless the context clearly dictates otherwise.

[0008] As used herein, "about" means + / - 5% of the specified numerical value.

[0009] In one aspect, the disclosure provides a composition comprising particles comprising at least 95% by weight of rucaparib, or a pharma- ceutically acceptable salt thereof, wherein the particles have a diameter of at least 12 mm. 2 / g. Such particles are referred to herein as "rucaparib particles."

[0010] As used herein, "rucaparib" includes any ionized state of rucaparib, including base, acid, and neutral states.

[0011] [ka] Chemical name of rucaparib: (8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[5,4,3-cd]indol-6-one ((1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl)

[0012] "Rucaparib particles" refers to particles of rucaparib, or a pharma- ceutically acceptable salt thereof, and does not include additional excipients. Rucaparib particles are different from "particles containing rucaparib", which are particles that include rucaparib and at least one additional excipient. The rucaparib particles of the present disclosure do not include polymeric, waxy, or protein excipients, and are not embedded, enclosed, enclosed, or encapsulated in solid excipients. However, the rucaparib particles of the present disclosure may include impurities and by-products that are typically found during the preparation of rucaparib. Nevertheless, the rucaparib particles include at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% rucaparib, or a pharma- ceutically acceptable salt thereof, meaning that the rucaparib particles consist of or essentially consist of substantially pure rucaparib or a pharma- ceutically acceptable salt of rucaparib.

[0013] As used herein, "specific surface area" is the total surface area of ​​rucaparib particles per unit of rucaparib mass as measured by the Brunauer-Emmett-Teller ("BET") isotherm (i.e.: BET SSA). As will be understood by those skilled in the art, the SSA is determined on a per gram basis and takes into account both aggregated and non-aggregated rucaparib particles in the composition. The BET specific surface area test procedure is an official method contained in both the United States Pharmacopoeia and the European Pharmacopoeia. The rucaparib particles have a specific surface area of ​​at least 12 m 2 In various further embodiments, the rucaparib particles have a specific surface area (SSA) of at least 13 m 2 / g, 14m 2 / g, 15m 2 / g, 16m 2 / g, 17m 2 / g, 18m2 / g, 19m 2 / g, 20m 2 / g, 21m 2 / g, 22m 2 / g, 23m 2 / g, 24m 2 / g, 25m 2 / g, 26m 2 / g, 27m 2 / g, 28m 2 / g, 29m 2 / g, or 30m 2 / g SSA.

[0014] In a further embodiment, the rucaparib particles have a molecular weight of 12m 2 / g~about 50m 2 / g, 12.5m 2 / g~about 50m 2 / g, approx. 13m 2 / g~about 50m 2 / g, approx. 14m 2 / g~about 50m 2 / g, approx. 15m 2 / g~about 50m 2 / g, approx. 16m 2 / g~about 50m 2 / g, approx. 17m 2 / g~about 50m 2 / g, approx. 18m 2 / g~about 50m 2 / g, approx. 19m 2 / g~about 50m 2 / g, about 20m 2 / g~about 50m 2 / g, 12m 2 / g ~ approx. 45m 2 / g, approx. 12.5m 2 / g ~ approx. 45m 2 / g, approx. 13m 2 / g~about 45m 2 / g, approx. 14m 2 / g~about 45m 2 / g, approx. 15m 2 / g~about 45m 2 / g, approx. 16m 2 / g ~ approx. 45m 2 / g, approx. 17m 2 / g~about 45m 2 / g, approx. 18m2 / g~about 45m 2 / g, approx. 19m 2 / g~about 45m 2 / g, about 20m 2 / g~about 45m 2 / g, 12m 2 / g~about 40m 2 / g, approx. 12.5m 2 / g~about 40m 2 / g, approx. 13m 2 / g~about 40m 2 / g, approx. 14m 2 / g~about 40m 2 / g, approx. 15m 2 / g~about 40m 2 / g, approx. 16m 2 / g~about 40m 2 / g, approx. 17m 2 / g~about 40m 2 / g, approx. 18m 2 / g~about 40m 2 / g, approx. 19m 2 / g~about 40m 2 / g, or about 20m 2 / g~about 40m 2 / g SSA.

[0015] In one embodiment, the rucaparib particles have a mean particle size by volume distribution (Dv50) of about 1.0 microns to about 10.0 microns in diameter. In some embodiments, the rucaparib particles have a mean particle size by volume distribution of about 1 micron to about 6 microns in diameter, or about 2 microns to about 6 microns in diameter. The rucaparib particles are in a size range that is unlikely to be transported out of the tumor by the systemic circulation, and further benefit from a high specific surface area to facilitate drug solubilization and release.

[0016] In one embodiment, the rucaparib particles have a mass of about 0.020 g / cm 3 ~Approx. 0.300g / cm 3 In various further embodiments, the rucaparib particles have an average bulk density (not tapped density) of about 0.020 g / cm 3 ~Approx. 0.300g / cm 3 , about 0.020g / cm3 ~ about 0.275 g / cm 3 , about 0.020 g / cm 3 ~ about 0.250 g / cm 3 , about 0.020 g / cm 3 ~ about 0.225 g / cm 3 , about 0.020 g / cm 3 ~ about 0.200 g / cm 3 , about 0.020 g / cm 3 ~ about 0.175 g / cm 3 , about 0.020 g / cm 3 ~ about 0.150 g / cm 3 , about 0.020 g / cm 3 ~ about 0.125 g / cm 3 , about 0.020 g / cm 3 ~ about 0.100 g / cm 3 , about 0.040 g / cm 3 ~ about 0.300 g / cm 3 , about 0.040 g / cm 3 ~ about 0.275 g / cm 3 , about 0.040 g / cm 3 ~ about 0.250 g / cm 3 , about 0.040 g / cm 3 ~ about 0.225 g / cm 3 , about 0.040 g / cm 3 ~ about 0.200 g / cm 3 , about 0.040 g / cm 3 ~ about 0.175 g / cm 3 , about 0.040 g / cm 3 ~ about 0.150 g / cm 3 , about 0.040 g / cm 3 ~ about 0.125 g / cm 3 , about 0.040 g / cm 3 ~ about 0.100 g / cm 3 , about 0.060 g / cm 3 ~ about 0.300 g / cm 3 , about 0.060 g / cm 3 ~ about 0.275 g / cm 3 , about 0.060 g / cm 3 ~ about 0.250 g / cm 3 , about 0.060 g / cm 3 ~ about 0.225 g / cm 3, about 0.060g / cm 3 ~Approx. 0.200g / cm 3 , about 0.060g / cm 3 ~Approx. 0.175g / cm 3 , about 0.060g / cm 3 ~Approx. 0.150g / cm 3 , about 0.060g / cm 3 ~Approx. 0.125g / cm 3 , or about 0.060 g / cm 3 ~Approx. 0.100g / cm 3 The average bulk density (not tapped density) is

[0017] In another embodiment, the rucaparib particles have a mass of about 0.050 g / cm 3 ~Approx. 0.400g / cm 3 In various further embodiments, the rucaparib particles have an average tap density of about 0.020 g / cm 3 ~Approx. 0.375g / cm 3 , about 0.020g / cm 3 ~Approx. 0.350g / cm 3 , about 0.020g / cm 3 ~Approx. 0.325g / cm 3 , about 0.020g / cm 3 ~Approx. 0.300g / cm 3 , about 0.020g / cm 3 ~Approx. 0.275g / cm 3 , about 0.020g / cm 3 ~Approx. 0.250g / cm 3 , about 0.020g / cm 3 ~Approx. 0.225g / cm 3 , about 0.020g / cm 3 ~Approx. 0.200g / cm 3 , about 0.020g / cm 3 ~Approx. 0.175g / cm 3 , about 0.020g / cm 3 ~Approx. 0.150g / cm 3 , about 0.020g / cm 3 ~Approx. 0.125g / cm 3 , about 0.040g / cm 3 ~Approx. 0.375g / cm 3 , about 0.040g / cm3 ~Approx. 0.350g / cm 3 , about 0.040g / cm 3 ~Approx. 0.325g / cm 3 , about 0.040g / cm 3 ~Approx. 0.300g / cm 3 , about 0.040g / cm 3 ~Approx. 0.275g / cm 3 , about 0.040g / cm 3 ~Approx. 0.250g / cm 3 , about 0.040g / cm 3 ~Approx. 0.225g / cm 3 , about 0.040g / cm 3 ~Approx. 0.200g / cm 3 , about 0.040g / cm 3 ~Approx. 0.175g / cm 3 , about 0.040g / cm 3 ~Approx. 0.150g / cm 3 , about 0.040g / cm 3 ~Approx. 0.125g / cm 3 , about 0.060g / cm 3 ~Approx. 0.375g / cm 3 , about 0.060g / cm 3 ~Approx. 0.350g / cm 3 , about 0.060g / cm 3 ~Approx. 0.325g / cm 3 , about 0.060g / cm 3 ~Approx. 0.300g / cm 3 , about 0.060g / cm 3 ~Approx. 0.275g / cm 3 , about 0.060g / cm 3 ~Approx. 0.250g / cm 3 , about 0.060g / cm 3 ~Approx. 0.225g / cm 3 , about 0.060g / cm 3 ~Approx. 0.200g / cm 3 , about 0.060g / cm 3 ~Approx. 0.175g / cm 3 , about 0.060g / cm 3 ~Approx. 0.150g / cm 3 , or about 0.060 g / cm 3 ~about 0.125gg / cm 3The average tap density is

[0018] As used herein, the bulk density (not tapped density) of a particle is the ratio of mass to volume (including interparticle excluded volume) of an untapped powder sample.

[0019] As used herein, tap density of a particle is obtained by mechanically tapping a graduated cylinder containing a sample until no significant further change in volume is observed.

[0020] The increased specific surface area and decreased bulk density of rucaparib particles results in a significant increase in dissolution rate, for example, compared to raw or milled rucaparib products. Dissolution occurs only at the solid / liquid interface. Therefore, a large specific surface area increases the dissolution rate due to the large number of molecules on the surface of the particles in contact with the dissolution medium. Bulk density takes into account the powder's macrostructure and interparticle space. Parameters that contribute to bulk density include particle size distribution, particle shape, and particle-to-particle affinity (i.e., cohesion). The lower the bulk density of the powder, the faster the dissolution rate. This is due to the ability of the dissolution medium to more easily penetrate the gaps or interparticle spaces and make greater contact with the surface of the particles. This provides a significant improvement for the use of rucaparib particles disclosed herein, for example, in tumor treatment.

[0021] In any of these various embodiments, the rucaparib particles may, for example, have at least 5×10 per rucaparib particle. -15 grams of rucaparib or a pharma- ceutically acceptable salt thereof, or about 1 × 10 per rucaparib particle -8 ~Approx. 5×10 -15 grams of rucaparib, or a pharma- ceutical acceptable salt thereof.

[0022] In one embodiment, the particles are uncoated and are free of polymers, proteins, polyethoxylated castor oil, and polyethylene glycol glycerides, which are composed of mono-, di-, and triglycerides and mono- and diesters of polyethylene glycol.

[0023] In further embodiments, the composition comprises a liquid suspension further comprising a pharma- ceutically acceptable liquid carrier. The suspension of the present disclosure comprises rucaparib particles and a liquid carrier. The liquid carrier may be aqueous or non-aqueous. Even if the rucaparib particles do not comprise additional excipients, the liquid carrier of the suspension may comprise water or a non-aqueous liquid, and optionally one or more excipients selected from the group consisting of a buffer, an isotonicity agent, a preservative, a demulcent, a viscosity modifier, an osmotic agent, a surfactant, an antioxidant, an alkalizing agent, an acidifying agent, an antifoaming agent, and a coloring agent. For example, the suspension may comprise rucaparib particles, water, a buffer, and a salt. In some cases, it may further comprise a surfactant. In some embodiments, the suspension consists essentially of or consists of water, rucaparib particles suspended in water, and a buffer. The suspension may further comprise an osmotic salt. In another example, the suspension may comprise rucaparib particles and a non-aqueous liquid, such as a liquefied gas propellant. Examples of liquefied gas propellants include, but are not limited to, hydrofluoroalkanes (HFAs). Examples of other non-aqueous liquids include, but are not limited to, mineral oil, vegetable oil, glycerin, polyethylene glycol, poloxamers that are liquid at room temperature (e.g., poloxamer 124), and polyethylene glycols that are liquid at room temperature (e.g., PEG 400 and PEG 600).

[0024] In one embodiment, the suspension further comprises one or more components selected from the group consisting of polysorbates, methylcellulose, polyvinylpyrrolidone, mannitol, and hydroxypropylmethylcellulose.

[0025] The suspension may include one or more surfactants. Suitable surfactants include, by way of example and without limitation, polysorbates, lauryl sulfate, acetylated monoglycerides, diacetylated monoglycerides, and poloxamers.

[0026] The suspension may include one or more isotonicity agents. Suitable isotonicity agents include, by way of example and without limitation, one or more inorganic salts, electrolytes, sodium chloride, potassium chloride, sodium phosphate, potassium phosphate, sodium, potassium sulfate, sodium and potassium bicarbonate, and alkaline earth metal inorganic salts, e.g., alkaline earth metal salts such as calcium and magnesium salts, mannitol, dextrose, glycerin, propylene glycol, and mixtures thereof.

[0027] In an embodiment particularly suitable for intraperitoneal (IP) administration, the suspension may be formulated to be hyperosmolar (hypertonic), hypoosmolar (hypotonic), or isotonic (isotonic) with respect to the fluid of the IP cavity. In some embodiments, the suspension may be isotonic with respect to the fluid in the IP cavity. In such embodiments, the osmolality of the suspension may range from about 200 to about 380, about 240 to about 340, about 280 to about 300, or about 290 mOsm / kg.

[0028] The suspension may include one or more buffering agents. Suitable buffering agents include, by way of example and without limitation, dibasic sodium phosphate, monobasic sodium phosphate, citric acid, sodium citrate, hydrochloric acid, sodium hydroxide, tris(hydroxymethyl)aminomethane, bis(2-hydroxyethyl)iminotris-(hydroxymethyl)methane, and sodium bicarbonate, as well as others known to those skilled in the art. Buffers are generally used to adjust the pH to a desired range for intraperitoneal use. Typically, a pH of about 5-9, 5-8, 6-7.4, 6.5-7.5, or 6.9-7.4 is desired.

[0029] The suspension may include one or more demulcents. Demulcents are agents that form a soothing film over mucous membranes such as the peritoneum and membranes that cover organs. Demulcents can relieve minor pain and inflammation and are sometimes referred to as mucosal protectants. Suitable demulcents, when used with another polymeric demulcent described herein, include cellulose derivatives in the range of about 0.2 to about 2.5%, such as sodium carboxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, and methylcellulose; about 0.01% gelatin; about 0.05 to about 1%, including about 0.05 to about 1%, polyols such as glycerin, polyethylene glycol 300, polyethylene glycol 400, polysorbate 80, and propylene glycol; about 0.1 to about 4% polyvinyl alcohol; about 0.1 to about 2% povidone; and from about 0.1% dextran 70.

[0030] The suspension may include one or more alkalinizing agents to adjust the pH. As used herein, the term "alkalinizing agent" is intended to mean a compound used to provide an alkaline medium. Such compounds include, by way of example and without limitation, ammonia solution, ammonium carbonate, potassium hydroxide, sodium carbonate, sodium bicarbonate, and sodium hydroxide, as well as others known to those skilled in the art.

[0031] The suspension may contain one or more acidifying agents to adjust pH. As used herein, the term "acidifying agent" is intended to mean a compound used to provide an acidic medium. Such compounds include, by way of example and without limitation, acetic acid, amino acids, citric acid, nitric acid, fumaric acid and other alphahydroxy acids, hydrochloric acid, ascorbic acid, and nitric acid, as well as others known to those skilled in the art.

[0032] The suspension may contain one or more antifoaming agents.As used herein, the term "antifoaming agent" is intended to mean a compound or compounds that prevent or reduce the amount of foam that forms on the surface of the fill composition.Suitable antifoaming agents include, by way of example and without limitation, dimethicone, simethicone (registered trademark), octoxynol, and others known to those skilled in the art.

[0033] The suspension may contain one or more viscosity modifiers that increase or decrease the viscosity of the suspension. Suitable viscosity modifiers include methylcellulose, hydroxypropylmethycellulose, mannitol and polyvinylpyrrolidone.

[0034] The suspension may include one or more osmotic agents, such as those used in peritoneal dialysis. Suitable osmotic agents include icodextrin (a glucose polymer), sodium chloride, potassium chloride, and salts also used as buffering agents.

[0035] In one embodiment, a liquid suspension of rucaparib particles may be aerosolized for pulmonary administration by inhalation, and the mass median aerodynamic diameter (MMAD) of the aerosol droplets of the liquid suspension may be any diameter suitable for use. In one embodiment, the aerosol droplets have a mass median diameter (MMAD) of about 0.5 μm to about 6 μm. In various further embodiments, the aerosol droplets have a diameter of about 0.5 μm to about 5.5 μm, about 0.5 μm to about 5 μm, about 0.5 μm to about 4.5 μm, about 0.5 μm to about 4 μm, about 0.5 μm to about 3.5 μm, about 0.5 μm to about 3 μm, about 0.5 μm to about 2.5 μm, about 0.5 μm to about 2 μm, about 1 μm to about 5.5 μm, about 1 μm to about 5 μm, about 1 μm to about 4.5 μm, about 1 μm to about 4 μm, about 1 μm to about 3.5 μm, about 1 μm to about 3 μm, about 1 μm to about 2.5 μm. , having a diameter of about 1 μm to about 2 μm, a diameter of about 1.5 μm to about 5.5 μm, a diameter of about 1.5 μm to about 5 μm, a diameter of about 1.5 μm to about 4.5 μm, a diameter of about 1.5 μm to about 4 μm, a diameter of about 1.5 μm to about 3.5 μm, a diameter of about 1.5 μm to about 3 μm, a diameter of about 1.5 μm to about 2.5 μm, a diameter of about 1.5 μm to about 2 μm, a diameter of about 2 μm to about 5.5 μm, a diameter of about 2 μm to about 5 μm, a diameter of about 2 μm to about 4.5 μm, a diameter of about 2 μm to about 4 μm, a diameter of about 2 μm to about 3.5 μm, a diameter of about 2 μm to about 3 μm, and a diameter of about 2 μm to about 2.5 μm. A suitable instrument for measuring the median aerodynamic diameter (MMAD) and geometric standard deviation (GSD) of aerosol droplets is a seven-stage aerosol sampler, such as a Mercer-style cascade impactor. The liquid suspension of rucaparib particles delivered by aerosol may be deposited in the airways by gravitational settling, inertial impaction, and / or diffusion. Any device suitable for generating aerosols may be used, including, but not limited to, metered dose inhalers (MDIs), pressurized metered dose inhalers (pMDIs), nebulizers, and soft mist inhalers.

[0036] In one embodiment, the dry powder composition of rucaparib particles may be aerosolized for pulmonary administration by inhalation, and the mass median aerodynamic diameter (MMAD) of the aerosolized dry powder composition may be any diameter suitable for use. The dry powder composition is formulated as a dry powder. The dry powder composition may comprise rucaparib particles alone, without a carrier, or may comprise rucaparib particles and a pharma- ceutically acceptable dry powder carrier, including one or more dry powder excipients. In one embodiment, the aerosolized dry powder composition has an MMAD of about 0.5 μm to about 6 μm in diameter. In various further embodiments, the aerosolized dry powder composition has a diameter of about 0.5 μm to about 5.5 μm, about 0.5 μm to about 5 μm, about 0.5 μm to about 4.5 μm, about 0.5 μm to about 4 μm, about 0.5 μm to about 3.5 μm, about 0.5 μm to about 3 μm, about 0.5 μm to about 2.5 μm, about 0.5 μm to about 2 μm, about 1 μm to about 5.5 μm, about 1 μm to about 5 μm, about 1 μm to about 4.5 μm, about 1 μm to about 4 μm, about 1 μm to about 3.5 μm, about 1 μm to about 3 μm, about 1 μm to about 2. 5 μm, about 1 μm to about 2 μm in diameter, about 1.5 μm to about 5.5 μm in diameter, about 1.5 μm to about 5 μm in diameter, about 1.5 μm to about 4.5 μm in diameter, about 1.5 μm to about 4 μm in diameter, about 1.5 μm to about 3.5 μm in diameter, about 1.5 μm to about 3 μm in diameter, about 1.5 μm to about 2.5 μm in diameter, about 1.5 μm to about 2 μm in diameter, about 2 μm to about 5.5 μm in diameter, about 2 μm to about 5 μm in diameter, about 2 μm to about 4.5 μm in diameter, about 2 μm to about 4 μm in diameter, about 2 μm to about 3.5 μm in diameter, about 2 μm to about 3 μm in diameter, and about 2 μm to about 2.5 μm in diameter. Suitable instruments for measuring the median aerodynamic diameter (MMAD) and geometric standard deviation (GSD) of dry powder compositions are a seven-stage aerosol sampler such as a Mercer-style cascade impactor or an aerodynamic particle sizer spectrometer such as the APS™ Model 3321 spectrometer available from TSI Inc. Dry powder compositions delivered by aerosol may be deposited in the respiratory tract by gravitational settling, inertial impaction, and / or diffusion.Any device suitable for generating an aerosol of the dry powder composition may be used, including but not limited to a dry powder inhaler (DPI). Examples of excipients suitable for dry powder inhalable compositions include, but are not limited to, lactose of a grade suitable for inhalation. In one embodiment, the composition is a dry powder composition suitable for pulmonary delivery by inhalation via aerosolization.

[0037] As used herein, "pharmaceutically acceptable salts" of rucaparib are, within the scope of sound medical judgment, suitable for use in contact with patient tissues without undue toxicity, irritation, allergic response, etc., commensurate with a reasonable benefit / risk ratio, and effective for their intended use, including, where possible, zwitterionic forms of rucaparib. The term "salts" refers to relatively non-toxic, inorganic and organic acid addition salts of rucaparib. Representative salts include hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, malate, borate, benzoate, lactate, phosphate, tosylate, camsylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, and laurylsulfonate, etc. These may include cations based on alkali and alkaline earth metals such as sodium, lithium, potassium, calcium, magnesium, and the like, as well as non-toxic ammonium, quaternary ammonium, and amine cations, including, but not limited to, ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. (See, e.g., Berge SM et al., "Pharmaceutical Salts", J. Pharm. Sci., 1977;66:1-19, incorporated herein by reference.) In one embodiment, a pharma- ceutically acceptable salt of rucaparib has the following structure:

[0038] [ka]

[0039] Contains rucaparib camsylate.

[0040] In one embodiment, the composition comprises a dosage form of rucaparib in a suspension (i.e.: together with a pharma- ceutically acceptable carrier and any other ingredients) at a dosage deemed appropriate by the attending physician for the intended use. Any suitable dosage form may be used, and in various non-limiting embodiments, the dosage form is sufficient to provide from about 0.01 mg / kg to about 50 mg / kg of body weight per day. In various further embodiments, the dosage form is sufficient to provide about 0.01 mg / kg to about 45 mg / kg, about 0.01 mg / kg to about 40 mg / kg, about 0.01 mg / kg to about 35 mg / kg, about 0.01 mg / kg to about 30 mg / kg, about 0.01 mg / kg to about 25 mg / kg, about 0.01 mg / kg to about 20 mg / kg, about 0.01 mg / kg to about 15 mg / kg, about 0.01 mg / kg to about 10 mg / kg, about 0.01 mg / kg to about 5 mg / kg, or about 0.01 mg / kg to about 1 mg / kg of body weight per day. The suspension may be administered as or diluted with a diluent, such as saline for injection, optionally including a buffer and one or more other excipients, prior to administration. For example, the volume ratio of the suspension to the diluent may be within the range of 1:1 to 1:100 (v / v) or other suitable ratio.

[0041] In another aspect, the present disclosure provides a method for treating tumors, comprising administering to a subject having a tumor an effective amount of a composition or suspension of any embodiment or combination of embodiments of the present disclosure to treat the tumor.The increased specific surface area of ​​the rucaparib particles of the present disclosure results in a significant increase in the dissolution rate of the particles compared to currently available rucaparib.This provides a significant improvement for the use of the particles of the present disclosure, for example, in treating tumors.In addition, in some embodiments, the method of the present disclosure can reduce the dosing frequency and side effects of rucaparib.As a non-limiting example, since the systemic concentration is greatly reduced, the rucaparib dose administered by direct injection into tumors is expected to be substantially lower, the dosing frequency is lower compared to oral dosing, and there are fewer side effects.

[0042] As used herein, "tumor" includes benign tumors, precancerous tumors, malignant tumors that have not metastasized, and malignant tumors that have metastasized. The method of the present disclosure can be used to treat tumors that are amenable to rucaparib treatment, including but not limited to carcinoma, breast tumor, pancreatic tumor, prostate tumor, fallopian tube tumor, peritoneal tumor, bladder tumor, lung tumor, ovarian tumor, gastrointestinal tumor, testicular tumor, cervical tumor, head and neck tumor, esophageal tumor, mesothelioma, brain tumor, neuroblastoma, or renal cell tumor. In certain embodiments, the tumor is a fallopian tube tumor, a peritoneal tumor, a prostate tumor, or an ovarian tumor; in other embodiments, the tumor is a recurrent epithelial ovarian cancer, a fallopian tube tumor, or a primary peritoneal tumor that has a complete or partial response to platinum-based chemotherapy, or a metastatic castration-resistant prostate cancer with a BRCA mutation.

[0043] In another embodiment, the method further comprises administering to the subject an additional therapeutic agent, including but not limited to, an anthracycline, an antimetabolite, an alkylating agent (including but not limited to cisplatin), an alkaloid, a taxane (including but not limited to paclitaxel, docetaxel, cabazitaxel, and combinations thereof), and / or a topoisomerase inhibitor.

[0044] The subject may be any suitable subject with a tumor, including but not limited to humans, primates, dogs, cats, horses, cattle, etc. In one embodiment, the subject is a human subject. In some embodiments, the subject being treated with two or more chemotherapy, such as a human subject, has epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer associated with a deleterious BRCA mutation (germline and / or somatic). In another embodiment, the subject being treated with androgen receptor targeted therapy and taxane-based chemotherapy, such as a human subject, has metastatic castration-resistant prostate cancer (mCRPC) associated with a deleterious BRCA mutation (germline and / or somatic).

[0045] As used herein, "treat" or "treating" means achieving one or more of the following: (a) reducing the severity of the disorder; (b) limiting or preventing the onset of symptoms characteristic of the disorder being treated; (c) inhibiting or exacerbating symptoms characteristic of the disorder being treated; (d) limiting or preventing the recurrence of the disorder in a patient who already has the disorder; and (e) limiting or preventing the recurrence of symptoms in a patient who is previously symptomatic of the disorder.

[0046] The amount effective for these uses will depend on factors including, but not limited to, the nature of rucaparib (such as specific activity), the route of administration, the stage and severity of the disorder, the subject's weight and general health, and the judgment of the prescribing physician. It will be understood that the amount of the suspension composition of the present disclosure actually administered will be determined by the physician in light of the relevant circumstances described above. In one non-limiting embodiment, the effective amount is an amount that provides 0.01 mg / kg to about 50 mg / kg body weight per day.

[0047] In further embodiments, the composition comprises a liquid suspension further comprising a pharmacy acceptable liquid carrier. The suspension of the present disclosure comprises rucaparib particles and a liquid carrier. All of the suspension, liquid carrier embodiments disclosed herein can be used in the therapeutic methods of the present disclosure.

[0048] In one embodiment, a liquid suspension of rucaparib particles for use in therapy may be aerosolized for pulmonary administration by inhalation, and the mass median aerodynamic diameter (MMAD) of the aerosolized droplets of the liquid suspension may be of any suitable diameter for use, and all embodiments disclosed herein may be used in the therapy of the present disclosure.

[0049] In one embodiment, the dry powder composition of rucaparib particles for use in the method of treatment may be aerosolized for pulmonary administration by inhalation, and the mass median aerodynamic diameter (MMAD) of the aerosolized dry powder composition may be any suitable diameter for use, and all embodiments disclosed herein may be used in the method of treatment of the present disclosure. The dry powder composition delivered by aerosol may be deposited in the airways by gravitational settling, inertial impaction, and / or diffusion. Any device suitable for generating an aerosol of the dry powder composition may be used in the method of treatment of the present disclosure, including but not limited to a dry powder inhaler (DPI). Examples of excipients suitable for the dry powder inhalable composition include, but are not limited to, lactose of a grade suitable for inhalation. In one embodiment, the composition is a dry powder composition administered by inhalation via aerosolization.

[0050] In one embodiment, the composition comprises a dosage form of rucaparib in a suspension (i.e.: together with a pharma- ceutically acceptable carrier and any other ingredients) at a dosage deemed appropriate by the attending physician for the intended use. Any suitable dosage form may be used, and in various non-limiting embodiments, the dosage form is sufficient to provide from about 0.01 mg / kg to about 50 mg / kg of body weight per day. In various further embodiments, the dosage form is sufficient to provide about 0.01 mg / kg to about 45 mg / kg, about 0.01 mg / kg to about 40 mg / kg, about 0.01 mg / kg to about 35 mg / kg, about 0.01 mg / kg to about 30 mg / kg, about 0.01 mg / kg to about 25 mg / kg, about 0.01 mg / kg to about 20 mg / kg, about 0.01 mg / kg to about 15 mg / kg, about 0.01 mg / kg to about 10 mg / kg, about 0.01 mg / kg to about 5 mg / kg, or about 0.01 mg / kg to about 1 mg / kg of body weight per day. A suspension that is or can be diluted with a diluent may be administered.

[0051] The compositions may be administered via any appropriate route, including but not limited to oral, pulmonary, intraperitoneal, intratumoral, peritumoral, subcutaneous injection, intramuscular injection, administration into the mammary fat pad, or any other form of injection, as deemed most suitable by the attending medical practitioner in light of all factors relevant to the particular subject.

[0052] In one embodiment, pulmonary administration includes inhalation of a single dose of rucaparib particles, such as by nasal inhalation, oral inhalation, or both. Rucaparib particles may be administered in two or more separate administrations (doses). In this embodiment, the particles may be formulated as an aerosol (i.e.: liquid droplets of a stable dispersion or suspension of particles in a gas medium). Rucaparib particles delivered by aerosol may be deposited in the airways by gravitational settling, inertial impaction, and / or diffusion. Any device suitable for generating aerosols may be used, including, but not limited to, metered dose inhalers (MDIs), pressurized metered dose inhalers (pMDIs), nebulizers, and soft mist inhalers.

[0053] In a particular embodiment, the method comprises inhalation of aerosolized rucaparib particles via nebulization. Nebulizers typically use compressed air or ultrasonic power to generate inhalable aerosol droplets of particles or a suspension thereof. In this embodiment, nebulization results in pulmonary delivery of aerosol droplets of rucaparib particles or a suspension thereof to the subject.

[0054] In another embodiment, the method comprises inhalation of aerosolized rucaparib particles via a pMDI, where the particles or a suspension thereof are suspended in at least one liquefied gas containing a suitable propellant system (including but not limited to hydrofluoroalkanes (HFAs)) in a pressurized container sealed with a metering valve. Actuation of the valve results in delivery of a metered dose of an aerosol spray of the rucaparib particles or a suspension thereof.

[0055] In another embodiment, the method comprises inhaling a dry powder composition of rucaparib via a DPI, the dry powder composition comprising rucaparib particles alone without a carrier. In yet another embodiment, the method comprises inhaling a dry powder composition of rucaparib via a DPI, the dry powder composition comprising rucaparib particles and may comprise a pharma- ceutically acceptable dry powder carrier comprising one or more dry powder excipients. Examples of suitable dry powder excipients for dry powder inhalable compositions include, but are not limited to, lactose of a grade suitable for inhalation.

[0056] A dosing period is the period during which a dose of rucaparib particles in a composition or suspension is administered. A dosing period can be a single period during which the entire dose is administered, or it can be divided into two or more periods during which a portion of the dose is administered.

[0057] The post-dosing period is the period that begins after the completion of the previous dosing period and ends after the initiation of the subsequent dosing period. The duration of the post-dosing period can be changed depending on the subject's clinical response to rucaparib. No suspension is administered during the post-dosing period. The post-dosing period can last for at least 7 days, at least 14 days, at least 21 days, at least 28 days, at least 35 days, at least 60 days, or at least 90 days or more. The post-dosing period can be kept constant for a subject, or two or more different post-dosing periods can be used for a subject.

[0058] A dosing cycle includes a dosing period and a post-dosing period.Therefore, the duration of a dosing cycle is the sum of the dosing period and the post-dosing period.The dosing cycle can be kept constant for a subject, or two or more different dosing cycles can be used for a subject.

[0059] In one embodiment, administration is performed more than once, with each administration separated by at least 21 days.

[0060] In another aspect, the present disclosure provides a method for making rucaparib particles, comprising: (a) (i) introducing into a nozzle inlet a solution comprising at least one solvent, including but not limited to ethanol, methanol, hexafluoroisopropanol (HFIP), dimethylformamide (DMF), dimethylsulfoxide (DMSO), or a combination thereof, and at least one solute, including rucaparib or a pharma- ceutically acceptable salt thereof, and (ii) introducing a compressed fluid into an inlet of a container defining a pressurizable chamber; (b) passing the solution through a nozzle orifice into a pressurizable chamber to generate an outlet stream of atomized droplets, the nozzle orifice being located 2 mm to 20 mm from a sonic energy source located within the outlet stream, the sonic energy source generating sonic energy having an amplitude of 10% to 100% during the passage, and the nozzle orifice having a diameter of 20 μm to 125 μm; (c) contacting the atomized droplets with a compressed fluid to cause removal of solvent from the atomized droplets to produce rucaparib particles comprising at least 95% rucaparib or a pharma- ceutically acceptable salt thereof, wherein the rucaparib particles are at least 2.5 mm in diameter and have a diameter of at least 2.5 mm. 2 / g specific surface area (SSA), optionally having an average particle size by volume distribution (Dv50) of about 1.0 microns to about 10.0 microns in diameter; The method further comprises the steps of: (a), (b) and (c) being carried out at a temperature and pressure that is below the supercritical temperature and pressure of said compressed fluid.

[0061] The method utilizes a sonic energy source located directly in the exhaust stream of solutes dissolved in a solvent. Any suitable source of sonic energy compatible with the methods of the present disclosure may be used, including but not limited to a sonic horn, sonic probe, or sonic plate. In various embodiments, the nozzle orifice is located about 2 mm to about 20 mm, about 2 mm to about 18 mm, about 2 mm to about 16 mm, about 2 mm to about 14 mm, about 2 mm to about 12 mm, about 2 mm to about 10 mm, about 2 mm to about 8 mm, about 2 mm to about 6 mm, about 2 mm to about 4 mm, about 4 mm to about 20 mm, about 4 mm to about 18 mm, about 4 mm to about 16 mm, about 4 mm to about 14 mm, about 4 mm to about 12 mm, about 4 mm to about 10 mm, about 4 mm to about 8 mm, about 4 mm to about 6 mm, about 6 mm to about 20 mm, about 6 mm to about 18 mm, about 6 mm to about 16 mm, about 6 mm to about 14 mm, about 6 mm to about 12 mm, about 6 mm to about 6 ... m to about 10 mm, about 6 mm to about 8 mm, about 8 mm to about 20 mm, about 8 mm to about 18 mm, about 8 mm to about 16 mm, about 8 mm to about 14 mm, about 8 mm to about 12 mm, about 8 mm to about 10 mm, about 10 mm to about 20 mm, about 10 mm to about 18 mm, about 10 mm to about 16 mm, about 10 mm to about 14 mm, about 10 mm to about 12 mm, about 12 mm to about 20 mm, about 12 mm to about 18 mm, about 12 mm to about 16 mm, about 12 mm to about 14 mm, about 14 mm to about 20 mm, about 14 mm to about 18 mm, about 14 mm to about 16 mm, about 16 mm to about 20 mm, about 16 mm to about 18 mm, and about 18 mm to about 20 mm. In a further embodiment, the nozzle assembly of any embodiment of WO 2016 / 197091 may be used.

[0062] Any suitable source of sonic energy compatible with the methods of the present disclosure may be used, including, but not limited to, a sonic horn, a sonic probe, or a sonic plate. In various further embodiments, the sonic energy source produces sonic energy having an amplitude of about 10% to about 100% of the total power that can be generated using the sonic energy source. In light of the teachings herein, one of skill in the art can determine an appropriate sonic energy source having a particular total power output to be used. In one embodiment, the sonic energy source has a total power output of about 500 to about 900 watts; in various further embodiments, about 600 to about 800 watts, about 650 to 750 watts, or about 700 watts.

[0063] In various further embodiments, the sonic energy source is about 20% to about 100%, about 30% to about 100%, about 40% to about 100%, about 50% to about 100%, about 60% to about 100%, about 70% to about 100%, about 80% to about 100%, about 90% to about 100%, about 100% of the total power that can be generated using the sonic energy source. % to about 90%, about 20% to about 90%, about 30% to about 90%, about 40% to about 90%, about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 80% to about 90%, about 10% to about 80%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 60% to about 80%, about 70% to About 80%, about 10% to about 70%, about 20% to about 70%, about 30% to about 70%, about 40% to about 70%, about 50% to about 70%, about 60% to about 70%, about 10% to about 60%, about 20% to about 60%, about 30% to about 60%, about 40% to about 60%, about 50% to about 60%, about 10% to about 50%, about 20% to about 50%, about 30% to about The sonic energy source may generate sonic energy having an output of about 50%, about 40% to about 50%, about 10% to about 40%, about 20% to about 40%, about 30% to about 40%, about 10% to about 30%, about 20% to about 30%, about 10% to about 20%, or about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or about 100%. In light of the teachings herein, one of ordinary skill in the art can determine the appropriate frequency to be utilized in the sonic energy source. In one embodiment, a frequency of about 18 to about 22 kHz is utilized in the sonic energy source. In various other embodiments, a frequency of about 19 to about 21 kHz, about 19.5 to about 20.5, or about 20 kHz is utilized in the sonic energy source.

[0064] In various further embodiments, the nozzle orifice may be from about 20 μm to about 125 μm, from about 20 μm to about 115 μm, from about 20 μm to about 100 μm, from about 20 μm to about 90 μm, from about 20 μm to about 80 μm, from about 20 μm to about 70 μm, from about 20 μm to about 60 μm, from about 20 μm to about 50 μm, from about 20 μm to about 40 μm, from about 20 μm to about 30 μm, from about 30 μm to about 125 μm, from about 30 μm to about 115 μm, from about 30 μm to about 100 μm, from about 30 μm to about 9 0μm, about 30μm to about 80μm, about 30μm to about 70μm, about 30μm to about 60μm, about 30μm to about 50μm, about 30μm to about 40μm, about 40μm to about 125μm, about 40μm to about 115μm, about 40μm to about 1 00μm, about 40μm to about 90μm, about 40μm to about 80μm, about 40μm to about 70μm, about 40μm to about 60μm, about 40μm to about 50μm, about 50μm to about 125μm, about 50μm to about 115μm, about 50μm to about 1 00μm, about 50μm to about 90μm, about 50μm to about 80μm, about 50μm to about 70μm, about 50μm to about 60μm, about 60μm to about 125μm, about 60μm to about 115μm, about 60μm to about 100μm, about 60μm Approximately 90μm, approximately 60μm to approximately 80μm, approximately 60μm to approximately 70μm, approximately 70μm to approximately 125μm, approximately 70μm to approximately 115μm, approximately 70μm to approximately 100μm, approximately 70μm to approximately 90μm, approximately 70μm to approximately 80μm, approximately 80μm The nozzle has a diameter of about 125 μm, about 80 μm to about 115 μm, about 80 μm to about 100 μm, about 80 μm to about 90 μm, about 90 μm to about 125 μm, about 90 μm to about 115 μm, about 90 μm to about 100 μm, about 100 μm to about 125 μm, about 100 μm to about 115 μm, about 115 μm to about 125 μm, about 20 μm, 30 μm, 40 μm, 50 μm, 60 μm, 70 μm, 80 μm, 90 μm, 100 μm, 115 μm, or about 120 μm. The nozzle is inert to both the solvent and compressed fluid used in the method.

[0065] The solvent includes ethanol, methanol, hexafluoroisopropanol (HFIP), dimethylformamide (DMF), or a combination thereof. The solvent should comprise at least about 80%, 85%, or 90% by weight of the total solution.

[0066] The compressed fluid can form a supercritical fluid under the conditions used, and the solutes forming the particles are poorly soluble or insoluble in the compressed fluid. As known to those skilled in the art, a supercritical fluid is any substance at a temperature and pressure above its critical point, and no distinct liquid or gas phases exist. Steps (a), (b), and (c) of the method of the present disclosure are carried out under the supercritical temperature and pressure of the compressed fluid, so that the compressed fluid exists as a supercritical fluid during these processing steps.

[0067] The compressed fluid can function as a solvent and can be used to remove unwanted components within the particles. Any suitable compressed fluid may be used in the disclosed method; such representative compressed fluids are disclosed in U.S. Pat. Nos. 5,833,891 and 5,874,029. In one non-limiting embodiment, suitable supercritical fluid forming compressed fluids and / or anti-solvents can include carbon dioxide, ethane, propane, butane, isobutane, nitrous oxide, xenon, sulfur hexafluoride, and trifluoromethane. The anti-solvents listed in step (d) to cause further solvent removal are compressed fluids as defined above and may be the same compressed fluids used in steps (a-c) or may be different. In one embodiment, the anti-solvent used in step (d) is the same compressed fluid used in steps (a-c). In a preferred embodiment, the compressed fluid and anti-solvent are both supercritical carbon dioxide.

[0068] In all cases, the compressed fluid and anti-solvent should be substantially miscible with the solvent, but rucaparib should be substantially insoluble in the compressed fluid, i.e., rucaparib should be soluble at about 5% by weight or less in the compressed fluid or anti-solvent at the selected solvent / compressed fluid contact conditions, and preferably essentially completely insoluble.

[0069] The supercritical state used in the method of the present disclosure is typically within a range of 1 to about 1.4 times, or 1 to about 1.2 times, the critical temperature of the supercritical fluid, and within a range of 1 to about 7 times, or 1 to about 2 times, the supercritical pressure of the compressed fluid.

[0070] It is well within the level of one of ordinary skill in the art to determine the critical temperature and pressure for a given compressed fluid or anti-solvent. In one embodiment, the compressed fluid and anti-solvent are both supercritical carbon dioxide, the critical temperature is at least 31.1° C. and not more than about 60° C., and the critical pressure is at least 1071 psi and not more than about 1800 psi. In another embodiment, the compressed fluid and anti-solvent are both supercritical carbon dioxide, the critical temperature is at least 35° C. and not more than about 55° C., and the critical pressure is at least 1070 psi and not more than about 1500 psi. It will be understood by one of ordinary skill in the art that the specific critical temperatures and pressures may be different at various steps during processing.

[0071] Any suitable pressurizable chamber may be used, including but not limited to those disclosed in WO 2016 / 197091 or US Patent Nos. 5,833,891 and 5,874,029. Similarly, the step of contacting the atomized droplets with a compressed fluid to cause removal of the solvent from the droplets; and the step of contacting the droplets with an anti-solvent to cause further removal of the solvent from the droplets to produce particles of the compound may be carried out under any suitable conditions, including but not limited to those disclosed in US Patent Nos. 5,833,891 and 5,874,029.

[0072] The flow rate can be adjusted to be as high as possible to optimize the output, but below the pressure limits of the device including the nozzle orifice. In one embodiment, the flow rate of the solution through the nozzle ranges from about 0.5 mL / min to about 30 mL / min. In various further embodiments, the flow rate is about 0.5 mL / min to about 25 mL / min, 0.5 mL / min to about 20 mL / min, 0.5 mL / min to about 15 mL / min, 0.5 mL / min to about 10 mL / min, 0.5 mL / min to about 4 mL / min, about 1 mL / min to about 30 mL / min, about 1 mL / min to about 25 mL / min, about 1 mL / min to about 20 mL / min, 1 mL / min to about 15 mL / min, about 1 mL / min to about 10 mL / min, about 2 mL / min to about 30 mL / min, about 2 mL / min to about 25 mL / min, about 2 mL / min to about 20 mL / min, about 2 mL / min to about 15 mL / min, or about 2 mL / min to about 10 mL / min. The solution of the drug affected by the flow rate can be any suitable concentration, such as about 1 mg / ml to about 80 mg / ml.

[0073] In one embodiment, the method further includes receiving the plurality of particles through an outlet of the pressurizable chamber; and collecting the plurality of particles in a collection device such as disclosed in WO 2016 / 197091.

[0074] In another aspect, the present disclosure provides rucaparib particles prepared by a process of any embodiment or combination of embodiments of the present disclosure.

[0075] Working Example

[0076] [Table 1]

[0077] Material Testing Particle Size Distribution (PSD) by Laser Diffraction Scanning Electron Microscope (SEM) Imaging Specific surface area (SSA) measurement by BET yield measurement Crystalline / amorphous phase determination by powder X-ray diffraction (PXRD) Modified USP <616> Bulk density analysis of powders by method I.

[0078] the study 1. Solvent solubility study of rucaparib in various solvents. 2. Demonstration of precipitating rucaparib from a solvent system and subsequently analyzing the corresponding material for / by PSD, SEM, PXRD, SSA, and bulk density.

[0079] The solubility of rucaparib was tested in the following solvent mixtures: Ethanol only, Methanol only, HFIP only, DMF only, or DMSO only.

[0080] Precipitation experiments were performed with rucaparib on an RC612B precipitation unit. Precipitates from the experiments were analyzed by laser diffraction to determine the PSD, by SEM to determine the shape / properties supporting the PSD data, by BET yield measurements to determine the SSA, by PXRD to determine the crystalline / amorphous phase of the material, and by bulk density analysis to identify additional physical characteristics of the precipitate.

[0081] Experimental procedure Receiving materials Rucaparib was obtained from BOC Sciences and stored in a temperature-monitored refrigerator at 2–8 °C.

[0082] Solvent Selection Solubility in organic solvents greater than about 8 mg / mL at room temperature was deemed sufficient for further study, with higher solvent solubility resulting in shorter production times. Solubility was determined by visual observation and tested according to standard operating procedures.

[0083] Precipitation Following standard operating procedures, seven small precipitates of rucaparib were generated on an RC612B SCP unit.

[0084] In one particular representative method, a solution of 11.9 mg / mL of rucaparib was prepared in ethanol. The nozzle and sonic probe were positioned approximately 9 mm apart in a pressurizable chamber. A stainless steel membrane filter with a nominal rating of approximately 20 nm was attached to the pressurizable chamber to collect the precipitated rucaparib particles. Supercritical carbon dioxide was placed in the pressurizable chamber of the manufacturing facility at approximately -38°C and approximately 1200 psi with a flow rate of 4-12 kg / hr. The sonic probe was adjusted to an amplitude of 60% of maximum output with a frequency of 20 kHz. The ethanol solution containing rucaparib was pumped through the nozzle at a flow rate of 2 mL / min for approximately 21 minutes. The precipitated rucaparib particles were then collected from the supercritical carbon dioxide while the mixture was pumped through a stainless steel mesh filter. The filter containing the rucaparib particles was opened and the resulting product was collected from the filter. Two larger experiments using a solution concentration of 11.0 mg / ml were performed using the same conditions. Run times were approximately 437 minutes and 402 minutes for the two large batches.

[0085] In one particular representative method, a solution of 12.5 mg / mL rucaparib was prepared in methanol. The nozzle and sonic probe were positioned approximately 9 mm apart in a pressurizable chamber. A stainless steel membrane filter with a nominal rating of approximately 20 nm was attached to the pressurizable chamber to collect precipitated rucaparib particles. Supercritical carbon dioxide was placed in the pressurizable chamber of the manufacturing facility at approximately 38°C and approximately 1200 psi with a flow rate of 4-12 kg / hr. The sonic probe was adjusted to an amplitude of 60% of maximum output with a frequency of 20 kHz. The methanol solution containing rucaparib was pumped through the nozzle at a flow rate of 2 mL / min for approximately 20 minutes. The precipitated rucaparib particles were then collected from the supercritical carbon dioxide while the mixture was pumped through a stainless steel mesh filter. The filter containing the rucaparib particles was opened and the resulting product was collected from the filter.

[0086] In one particular representative method, a 50 mg / mL solution of rucaparib was prepared in HFIP. The nozzle and sonic probe were positioned approximately -9 mm apart in a pressurizable chamber. A stainless steel membrane filter with a nominal rating of approximately 20 nm was attached to the pressurizable chamber to collect precipitated rucaparib particles. Supercritical carbon dioxide was placed in the pressurizable chamber of the manufacturing facility at approximately 38°C and approximately 1200 psi with a flow rate of 4-12 kg / hr. The sonic probe was adjusted to an amplitude of 60% of maximum output with a frequency of 20 kHz. The HFIP solution containing rucaparib was pumped through the nozzle at a flow rate of 2 mL / min for approximately 5 minutes. The precipitated rucaparib particles were then collected from the supercritical carbon dioxide while the mixture was pumped through a stainless steel mesh filter. The filter containing the rucaparib particles was opened and the resulting product was collected from the filter.

[0087] In one particular representative method, a solution of 51 mg / mL rucaparib was prepared in DMF. The nozzle and sonic probe were positioned approximately 9 mm apart in a pressurizable chamber. A stainless steel membrane filter with a nominal rating of approximately 20 nm was attached to the pressurizable chamber to collect precipitated rucaparib particles. Supercritical carbon dioxide was placed in the pressurizable chamber of the manufacturing facility at approximately 38°C and approximately 1200 psi with a flow rate of 4-12 kg / hr. The sonic probe was adjusted to an amplitude of 60% of maximum output with a frequency of 20 kHz. The DMF solution containing rucaparib was pumped through the nozzle at a flow rate of 2 mL / min for approximately 5 minutes. The precipitated rucaparib particles were then collected from the supercritical carbon dioxide while the mixture was pumped through a stainless steel mesh filter. The filter containing the rucaparib particles was opened and the resulting product was collected from the filter.

[0088] In one particular representative method, a 50 mg / mL solution of rucaparib was prepared in DMSO. The nozzle and sonic probe were positioned approximately 9 mm apart in a pressurizable chamber. A stainless steel membrane filter with a nominal rating of approximately 20 nm was attached to the pressurizable chamber to collect precipitated rucaparib particles. Supercritical carbon dioxide was placed in the pressurizable chamber of the manufacturing facility at approximately 38° C. and approximately 1200 psi with a flow rate of 4-12 kg / hr. The sonic probe was adjusted to an amplitude of 60% of maximum output with a frequency of 20 kHz. The DMSO solution containing rucaparib was pumped through the nozzle at a flow rate of 2 mL / min for approximately 5 minutes. The precipitated rucaparib particles were then collected from the supercritical carbon dioxide while the mixture was pumped through a stainless steel mesh filter. The filter containing the rucaparib particles was opened and the resulting product was collected from the filter.

[0089] Analytical Testing Following the three rucaparib precipitation experiments, materials were analyzed for / by PSD, SEM, PXRD, SSA, and bulk density, where applicable.

[0090] Results and Discussion Precipitation Precipitation experiments were performed using DMF (SC1), DMSO (SC2), HFIP (SC3), methanol (SC4), and ethanol (SC5, SC6, and SC7). The grid for the precipitation experiments can be seen in Table 1.

[0091] [Table 2]

[0092] Particle size distribution Particle size analysis was performed on a Malvern Mastersizer™ 3000 using a Hydro MV™ dispersion unit. Rucaparib samples were analyzed using an unvalidated generic PSD / dispersant method. The sample preparation procedure performed was as follows: weigh 10-20 mg of rucaparib into a 30 mL vial and add 20 mL of ethyl acetate. Disperse the sample by vortexing the suspension for 1 min in an ultrasonic bath and then sonicating. The sample suspension is then transferred to a Malvern Hydro MV™ dispersion unit to obtain a decay rate of 5-15%.

[0093] The particle size distribution can be seen in Table 1.

[0094] Scanning electron microscopy Scanning electron microscopy was performed on a Joel NeoScope™ SEM. Overall, the imaging supports the particle size distribution results with varying distribution and various particle shapes / properties. Representative SEM micrographs can be seen in Figures 1-7.

[0095] Powder X-ray diffraction Powder X-ray diffraction analysis was performed on a Siemens D5000 X-ray diffractometer. PXRD was scanned from 5 to 35 2θ degrees at a speed of 0.02 2θ degrees / sec and 1 sec per step. Representative diffraction pattern overlays can be seen in Figures 8-9. Experiments SC1, SC3, SC4 and SC5 were amorphous powders. Experiments SC6 and SC7 were crystalline and in various polymorphic crystalline forms than the crude product.

[0096] specific surface area Surface area analysis was performed on a Quantachrome NOVAtouch™ LX2 BET Sorptometer. The surface area results can be found in Table 1.

[0097] Solubility Test The solubility was measured by using the shake flask method. Drug was added in duplicate excess to each solution prepared. The vials were placed on a mechanical shaker at 20-25°C for 24 hours. After shaking, the solutions were removed, filtered through 0.45 μm PTFE syringe filters, and analyzed by UV / Vis spectrophotometry. The results are shown in Table 2 and suggest that rucaparib exhibited concentration-dependent solubility.

[0098] [Table 3]

[0099] Dissolution Test The medium selected for dissolution testing was 900 mL of 25% methanol-water at 37° C. with a paddle speed of 50 rpm. To meet sink conditions, 20 mg of drug was added directly to each vessel. Two vessels contained treated SC7 material with a specific surface area measurement of 22.51 m2 / g and two vessels contained untreated material with a specific surface area measurement of 6.59 m2 / g. Time points were taken at 5, 15, 30, and 60 minutes. At each time point, a 5 mL aliquot was removed and immediately filtered through a 0.45 μm PTFE syringe filter, discarding the first 1 mL of filtrate. The solution was then analyzed by UV / visible spectrophotometry at a wavelength of 275 nm. The dissolution profile is depicted in FIG. 9 and shows the differentiation.

[0100] conclusion Rucaparib was successfully precipitated from all three solvent systems tested, and the resulting rucaparib particles exhibited significantly increased specific surface area and improved dissolution properties.

Claims

1. 1. A composition comprising particles comprising at least 95% by weight of rucaparib, or a pharma- ceutically acceptable salt thereof, wherein the particles have a diameter of at least 12 mm. 2 / g, 13m 2 / g, 14m 2 / g, 15m 2 / g, 16m 2 / g, 17m 2 / g, 18m 2 / g, 19m 2 / g, 20m 2 / g, 21m 2 / g, 22m 2 / g, 23m 2 / g, 24m 2 / g, 25m 2 / g, 26m 2 / g, 27m 2 / g, 28m 2 / g, 29m 2 / g, or 30m 2 / g specific surface area (SSA).

2. The particles are at least 13 m 2 The composition of claim 1 having an SSA of 0.1 to 0.5 g.

3. The particles are at least 18 m 2 The composition of claim 1 having an SSA of 0.1 to 0.5 g.

4. The particles are 12 m 2 / g ~ approx. 50m 2 / g, approximately 12.5m 2 / g ~ approx. 50m 2 / g, about 13m 2 / g ~ approx. 50m 2 / g, about 14m 2 / g ~ approx. 50m 2 / g, about 15m 2 / g ~ approx. 50m 2 / g, about 16m 2 / g ~ approx. 50m 2 / g, about 17m 2 / g ~ approx. 50m 2 / g, about 18m 2 / g ~ approx. 50m 2 / g, about 19m 2 / g ~ approx. 50m 2 / g, about 20m 2 / g ~ approx. 50m 2 / g, 12m 2 / g ~ approx. 45m 2 / g, approximately 12.5m 2 / g ~ approx. 45m 2 / g, about 13m 2 / g ~ approx. 45m 2 / g, about 14m 2 / g ~ approx. 45m 2 / g, about 15m 2 / g ~ approx. 45m 2 / g, about 16m 2 / g ~ approx. 45m 2 / g, about 17m 2 / g ~ approx. 45m 2 / g, about 18m 2 / g ~ approx. 45m 2 / g, about 19m 2 / g ~ approx. 45m 2 / g, about 20m 2 / g ~ approx. 45m 2 / g, 12m 2 / g ~ approx. 40m 2 / g, approximately 12.5m 2 / g ~ approx. 40m 2 / g, about 13m 2 / g ~ approx. 40m 2 / g, about 14m 2 / g ~ approx. 40m 2 / g, about 15m 2 / g ~ approx. 40m 2 / g, about 16m 2 / g ~ approx. 40m 2 / g, about 17m 2 / g ~ approx. 40m 2 / g, about 18m 2 / g ~ approx. 40m 2 / g, about 19m 2 / g ~ approx. 40m 2 / g, or about 20m 2 / g ~ approx. 40m 2 The composition of claim 1 having an SSA of 0.1 to 0.2 g / g.

5. 5. The composition of any one of claims 1 to 4, wherein the particles have an average particle size by volume distribution (Dv50) of from about 1.0 micron to about 10.0 microns in diameter, or from about 1 micron to about 6 microns in diameter, or from about 2 microns to about 6 microns in diameter.

6. 6. The composition of claim 1, wherein the particles comprise an amorphous powder or are crystalline.

7. The rucaparib particles have a density of about 0.020 g / cm 3 ~Approx. 0.300g / cm 3 7. The composition of claim 1 having an average bulk density (not tapped density) of

8. The rucaparib particles have a density of about 0.020 g / cm 3 ~Approx. 0.300g / cm 3 , about 0.020g / cm 3 ~Approx. 0.275g / cm 3 , about 0.020g / cm 3 ~Approx. 0.250g / cm 3 , about 0.020g / cm 3 ~Approx. 0.225g / cm 3 , about 0.020g / cm 3 ~Approx. 0.200g / cm 3 , about 0.020g / cm 3 ~Approx. 0.175g / cm 3 , about 0.020g / cm 3 ~Approx. 0.150g / cm 3 , about 0.020g / cm 3 ~Approx. 0.125g / cm 3 , about 0.020g / cm 3 ~Approx. 0.100g / cm 3 , about 0.040g / cm 3 ~Approx. 0.300g / cm 3 , about 0.040g / cm 3 ~Approx. 0.275g / cm 3 , about 0.040g / cm 3 ~Approx. 0.250g / cm 3 , about 0.040g / cm 3 ~Approx. 0.225g / cm 3 , about 0.040g / cm 3 ~Approx. 0.200g / cm 3 , about 0.040g / cm 3 ~Approx. 0.175g / cm 3 , about 0.040g / cm 3 ~Approx. 0.150g / cm 3 , about 0.040g / cm 3 ~Approx. 0.125g / cm 3 , about 0.040g / cm 3 ~Approx. 0.100g / cm 3 , about 0.060g / cm 3 ~Approx. 0.300g / cm 3 , about 0.060g / cm 3 ~Approx. 0.275g / cm 3 , about 0.060g / cm 3 ~Approx. 0.250g / cm 3 , about 0.060g / cm 3 ~Approx. 0.225g / cm 3 , about 0.060g / cm 3 ~Approx. 0.200g / cm 3 , about 0.060g / cm 3 ~Approx. 0.175g / cm 3 , about 0.060g / cm 3 ~Approx. 0.150g / cm 3 , about 0.060g / cm 3 ~Approx. 0.125g / cm 3 , or about 0.060 g / cm 3 ~Approx. 0.100g / cm 3 8. The composition of claim 7 having an average bulk density (not tapped density) of

9. The rucaparib particles have a density of about 0.020 g / cm 3 ~Approx. 0.400g / cm 3 The composition of claim 1 having an average tap density of

10. The rucaparib particles have a density of about 0.020 g / cm 3 ~Approx. 0.375g / cm 3 , about 0.020g / cm 3 ~Approx. 0.350g / cm 3 , about 0.020g / cm 3 ~Approx. 0.325g / cm 3 , about 0.020g / cm 3 ~Approx. 0.300g / cm 3 , about 0.020g / cm 3 ~Approx. 0.275g / cm 3 , about 0.020g / cm 3 ~Approx. 0.250g / cm 3 , about 0.020g / cm 3 ~Approx. 0.225g / cm 3 , about 0.020g / cm 3 ~Approx. 0.200g / cm 3 , about 0.020g / cm 3 ~Approx. 0.175g / cm 3 , about 0.020g / cm 3 ~Approx. 0.150g / cm 3 , about 0.020g / cm 3 ~Approx. 0.125g / cm 3 , about 0.040g / cm 3 ~Approx. 0.375g / cm 3 , about 0.040g / cm 3 ~Approx. 0.350g / cm 3 , about 0.040g / cm 3 ~Approx. 0.325g / cm 3 , about 0.040g / cm 3 ~Approx. 0.300g / cm 3 , about 0.040g / cm 3 ~Approx. 0.275g / cm 3 , about 0.040g / cm 3 ~Approx. 0.250g / cm 3 , about 0.040g / cm 3 ~Approx. 0.225g / cm 3 , about 0.040g / cm 3 ~Approx. 0.200g / cm 3 , about 0.040g / cm 3 ~Approx. 0.175g / cm 3 , about 0.040g / cm 3 ~Approx. 0.150g / cm 3 , about 0.040g / cm 3 ~Approx. 0.125g / cm 3 , about 0.060g / cm 3 ~Approx. 0.375g / cm 3 , about 0.060g / cm 3 ~Approx. 0.350g / cm 3 , about 0.060g / cm 3 ~Approx. 0.325g / cm 3 , about 0.060g / cm 3 ~Approx. 0.300g / cm 3 , about 0.060g / cm 3 ~Approx. 0.275g / cm 3 , about 0.060g / cm 3 ~Approx. 0.250g / cm 3 , about 0.060g / cm 3 ~Approx. 0.225g / cm 3 , about 0.060g / cm 3 ~Approx. 0.200g / cm 3 , about 0.060g / cm 3 ~Approx. 0.175g / cm 3 , about 0.060g / cm 3 ~Approx. 0.150g / cm 3 , or about 0.060 g / cm 3 ~Approx. 0.125gg / cm 3 The composition of claim 1 having an average tap density of

11. 11. The composition of any one of claims 1 to 10, wherein the particles comprise at least 96%, 97%, 98%, 99%, or 100% by weight of rucaparib, or a pharma- ceutically acceptable salt thereof.

12. 12. The composition of any one of claims 1 to 11, wherein the particles are uncoated and free of polymers, proteins, polyethoxylated castor oil, and polyethylene glycol glycerides composed of mono-, di- and triglycerides and mono- and diesters of polyethylene glycol.

13. 13. The composition of any one of claims 1 to 12, comprising a suspension further comprising a pharma- ceutically acceptable liquid carrier.

14. 14. The composition of any one of claims 1 to 13, further comprising one or more ingredients selected from the group consisting of polysorbates, methylcellulose, polyvinylpyrrolidone, mannitol, and hydroxypropyl methylcellulose.

15. 15. The composition of any one of claims 13 to 14, wherein the suspension is aerosolized and the mass median aerodynamic diameter (MMAD) of the aerosol droplets of the suspension can be any suitable diameter for use, such as from about 0.5 μm to about 6 μm in diameter.

16. (a) the composition is a dry powder composition, the dry powder composition does not include a carrier or any excipients, the dry powder composition is aerosolized, and the MMAD of the aerosolized dry powder composition can be any suitable diameter for use, such as from about 0.5 μm to about 6 μm in diameter; or (b) the composition is a dry powder composition, the dry powder composition comprising a pharma- ceutically acceptable dry powder carrier including one or more dry powder excipients, the dry powder composition being aerosolized, and the MMAD of the aerosolized dry powder composition can be any suitable diameter for use, such as from about 0.5 μm to about 6 μm in diameter; 13. The composition according to any one of claims 1 to 12.

17. 17. The composition of any one of claims 1 to 16, wherein the pharma- ceutically acceptable salt of rucaparib comprises rucaparib camsylate.

18. 20. A method of treating a tumor comprising administering to a subject having a tumor an amount of a composition described in any one of claims 1 to 17 effective to treat the tumor.

19. 19. The method of claim 18, wherein the tumor comprises a carcinoma, a breast tumor, a pancreatic tumor, a prostate tumor, a fallopian tube tumor, a peritoneal tumor, a bladder tumor, a lung tumor, an ovarian tumor, a gastrointestinal tumor, a testicular tumor, a cervical tumor, a head and neck tumor, an esophageal tumor, a mesothelioma, a brain tumor, a neuroblastoma, or a renal cell tumor; optionally, the tumor is a fallopian tube tumor, a peritoneal tumor, a prostate tumor, or an ovarian tumor; optionally, the tumor is a recurrent epithelial ovarian cancer, a fallopian tube tumor, or a primary peritoneal tumor that has had a complete or partial response to platinum-based chemotherapy, or a metastatic castration-resistant prostate cancer with a BRCA mutation.

20. 20. The method of claim 18 or 19, further comprising an additional therapeutic agent for the subject, including but not limited to anthracyclines, antimetabolites, alkylating agents (including but not limited to cisplatin), alkaloids, taxanes (including but not limited to paclitaxel, docetaxel, cabazitaxel, and combinations thereof), and / or topoisomerase inhibitors.

21. 21. The method of any one of claims 18 to 20, wherein the subject is a human subject.

22. 22. The method of any one of claims 18 to 21, wherein the composition is administered by intratumoral injection, peritumoral injection, intraperitoneal injection, pulmonary administration, or administered to the mammary fat pad.

23. 1. A method for making rucaparib particles, comprising: (a) (i) introducing into a nozzle inlet a solution comprising at least one solvent, including but not limited to ethanol, methanol, hexafluoroisopropanol (HFIP), dimethylformamide (DMF), dimethylsulfoxide (DMSO), or combinations thereof, and at least one solute, including rucaparib or a pharma- ceutically acceptable salt thereof, and (ii) introducing a compressed fluid into an inlet of a container defining a pressurizable chamber; (b) passing the solution through a nozzle orifice into the pressurizable chamber to generate an outlet stream of atomized droplets, the nozzle orifice being located 2mm to 20mm from a sonic energy source located within the outlet stream, the sonic energy source generating sonic energy having an amplitude of 10% to 100% during the passage, and the nozzle orifice having a diameter of 20μm to 125μm; (c) contacting the atomized droplets with the compressed fluid to cause removal of the solvent from the atomized droplets to produce rucaparib particles comprising at least 95% rucaparib or a pharma- ceutically acceptable salt thereof, wherein the rucaparib particles have a molecular weight of at least 12 mm. 2 / g specific surface area (SSA), optionally having an average particle size by volume distribution (Dv50) of about 1.0 microns to about 10.0 microns in diameter; The method of claim 1, wherein steps (a), (b), and (c) are carried out at a temperature and pressure that is supercritical of said compressed fluid.

24. 24. The method of claim 23, further comprising: (d) contacting the compound particles produced in step (c) with an anti-solvent to cause further removal of the solvent from the compound particles, wherein step (d) is carried out under a supercritical temperature and pressure of the anti-solvent.

25. 25. The method of any one of claims 23 to 24, wherein the flow rate of the solution through the nozzle ranges from about 0.5 mL / min to about 30 mL / min.

26. 26. The method of any one of claims 23 to 25, wherein the sonic energy source comprises one of a sonic horn, a sonic probe, or a sonic plate.

27. 27. The method of any one of claims 23 to 26, wherein the sonic energy source has a frequency of about 18 kHz to about 22 kHz, or about 20 kHz.

28. (e) receiving the plurality of particles through the outlet of the pressurizable chamber; and (f) collecting the plurality of particles in a collection device.

28. The method of any one of claims 23 to 27, further comprising:

29. 29. The method of any one of claims 23 to 28, wherein the compressed fluid is supercritical carbon dioxide.

30. 30. The method of any one of claims 23 to 29, wherein the anti-solvent is supercritical carbon dioxide.

31. 31. The method of any one of claims 23 to 30, carried out at 31.1°C to about 60°C and at about 1071 psi to about 1800 psi.

32. The particles are at least 18 m 2 32. The method of any one of claims 23 to 31, having an SSA of 0.01 to 0.1 g.

33. 33. Rucaparib particles prepared by the method of any one of claims 23 to 32.